SALSA MLPA Reagent Kits for Endocrine & Reproductive

MRC HOLLAND SALSA MLPA Reagent Kits for Endocrine & Reproductive in India

More Views

SALSA MLPA Reagent Kits for Endocrine & Reproductive
MLPA (Multiplex Ligation-dependant Probe Amplification (MLPA) is a multiplex PCR method that enables the copy number variation (CV) detection of up to 60 DNA sequences in a single reaction. 96 DNA samples can be handled simultaneously with results being available within 24 hours
Read More
Add to Shortlist

Features & Benefits

  • Endocrine & Reproductive disease detection
  • Simultaneous Detection of copy number, methylation and known point mutation
  • Low Input - Requires only 50 ng of DNA
  • Reproducible - High concordance with other techniques
  • Time Efficient - Results available within 24 hrs.
  • High Throughput - Can detect up to 60 sequences in 96  DNA samples, in one reactions
  • Cost Effective

Product Details

MLPA® is the gold standard for DNA copy number quantification and is used to study both hereditary disorders and tumours. MLPA can also be applied to investigate the methylation status of DNA sequences. MRC-Holland, the inventor and manufacturer of MLPA, offers 400 different MLPA panels. MLPA (Multiplex Ligation-dependant Probe Amplification (MLPA) is a multiplex PCR method that enables the copy number variation (CV) detection of up to 60 DNA sequences in a single reaction. 96 DNA samples can be handled simultaneously with results being available within 24 hours.


Components provided per SALSA MLPA Reagent Kit  



  • SALSA MLPA Buffer (yellow cap)

  • SALSA Ligase-65 (green cap)

  • Ligase Buffer A (transparent cap)

  • Ligase Buffer B (white cap)

  • SALSA PCR Primer Mix (brown cap)

  • SALSA Polymerase (orange cap) 


MLPA has the following solutions for Endocrine & Reproductive:
































































































































































PRODUCT NAMEAPPLICATIONREGION
ME031-GNASAlbright hereditary osteodystrophy (AHO), Pseudohypoparathyroidism (PHP)GNAS 20q13.32
ME033-TNDMTransient neonatal diabetes mellitus6q24
P017-MEN1Multiple endocrine neoplasiaMEN1 11q13
P049-SLC6A8 - ABCD1Creatine transporter, x-linkedSLC6A8, Xq28
P050-CAHCongenital Adrenal HyperplasiaCYP21A2 6p21.3
P074-ARAndrogen insensitivity syndrome (AIS)AR Xq12
P117-ABCC8Hyperinsulinemic hypoglycemia, familial (HHF1)ABCC8 11p15.1
P133-Kallmann-2Kallmann syndromeFGFR1 8p11.2, GNRHR 8p21, KISSR1 19p13.3 , GNRH1, NELF 9q34.3
P177-CASRHypocalciuric Hypercalcemia, familialCASR 3q13
P185-IntersexSex determinationSOX9 17q24.3; NR5A1 9q33; WNT4 1p36.12; CXorf21 & NROB1 Xp21.2
P216-GHD mix1Growth Hormone Deficiency (GHD)GH1, LHX4, POU1F1, HESX1, PROP1, GHRHR, LHX3
P217-IGF1RInsulin-like growth factor 1 receptor (IGF1R)IGFR1, IGFBP3.
P220-ObesityObesityLEPR, POMC, LEP, SIM1, MC3R, MC4R
P224-PPARGObesity, Diabetes mellitis type II, Familial partial lipodystrophy III, Colon cancerPPARG 3p25.2
P226-SDHParagangliomas (PGL)SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3
P234-GATA3 - GATA4Cardiac septal defectsGATA4 8p23, GATA3 10p15
P241-MODYMaturity-Onset Diabetes of the Young (MODY)MODY 1, 2, 3; 5
P244-AIP-MEN1-CDKN1BMultiple endocrine neoplasia (MEN)AIP 11q13, MEN1 11q13, CDKN1B 12p13
P251-NB mix 1Neuroblastoma1p36, 3p22/3p21.3 and 11q23
P252-NB mix 2Neuroblastoma2p24.1/MYCN, 2q33, 17p13/TP53, 17q
P253-NB mix 3NeuroblastomaChromosomes 4, 7, 9, 12, 14
P312-PORCongenital adrenal hyperplasia (CAH)P450 oxireductase gene (POR)
P319-ThyroidThyroid dysgenesisTPO, PAX8, FOXE1, NKX2-1, TSHR
P334-GonadalGonadal Development DisorderDMRT1, CYP17A1, SRD5A2, HSD17B3
P357-MODY mix-2Maturity-Onset Diabetes of the Young (MODY)MODY 4; 6-10
P360-Y-Chromosomebasic researchY-Chromosome MicrodeletionsChromosome Y
P429-SDHA-MAXParaganglioma and pheochromocytoma5p15.3 and 14q23.3
P461-DISDeafness Infertility Syndrome (DIS); non-syndromic hearing loss15q15.3; 16p12.2
P463-MRKHMayer-Rokitansky-Küster-Hauser Syndrome16p11.2; 17q12; 22q11.21
P466-CDC73HPT jaw tumour syndrome, famial hyperparathyroidism, parathyroid carcinomaCDC73


Read More